116 related articles for article (PubMed ID: 1528310)
1. Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen.
Bhatavdekar JM; Shah NG; Patel DD; Karelia NH; Trivedi SN; Vora HH; Ghosh N; Giri DD; Balar DB
Neoplasma; 1992; 39(2):123-7. PubMed ID: 1528310
[TBL] [Abstract][Full Text] [Related]
2. Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer.
Bianco AR; De Placido S; Pagliarulo C; Fasano S; D'Istria M; De Sio L; Ricciardi I; Delrio G
Chemioterapia; 1985 Jun; 4(3):252-5. PubMed ID: 3839720
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Sverrisdottir A; Nystedt M; Johansson H; Fornander T
Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
5. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients.
Dnistrian AM; Schwartz MK; Fracchia AA; Kaufman RJ; Hakes TB; Currie VE
Cancer; 1983 Mar; 51(5):803-7. PubMed ID: 6687378
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
Goldhirsch A; Gelber R
NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
[TBL] [Abstract][Full Text] [Related]
7. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
8. [Menstrual abnormality in patients with breast cancer receiving adjuvant endocrine-chemotherapy].
Yasumura T; Oka T; Honjo H; Okada H
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2947-52. PubMed ID: 3140733
[TBL] [Abstract][Full Text] [Related]
9. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients.
Rose DP; Davis TE
Cancer Res; 1980 Nov; 40(11):4043-7. PubMed ID: 6451282
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen.
Vorgias G; Koukouras D; Tzoracoeleftherakis E; Paleogianni V; Androulakis J
Anticancer Res; 2000; 20(5C):3849-54. PubMed ID: 11268466
[TBL] [Abstract][Full Text] [Related]
12. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
Neoplasma; 1985; 32(3):381-7. PubMed ID: 2862594
[TBL] [Abstract][Full Text] [Related]
13. Prolactin levels and hormonal profile in postmenopausal patients with advanced breast cancer during endocrine treatments.
Pannuti F; Martoni A; Farabegoli G; Piana E
Chemioterapia; 1985 Apr; 4(2):127-34. PubMed ID: 3159487
[TBL] [Abstract][Full Text] [Related]
14. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.
Jordan VC; Fritz NF; Tormey DC
Cancer Res; 1987 Jan; 47(2):624-30. PubMed ID: 3098415
[TBL] [Abstract][Full Text] [Related]
15. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
Johansen J; Overgaard J; Overgaard M
Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
17. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
Jiang Z; Song S; Liu X
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):420-2. PubMed ID: 11810777
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
19. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.
Tormey DC; Gray R; Taylor SG; Knuiman M; Olson JE; Cummings FJ
NCI Monogr; 1986; (1):75-80. PubMed ID: 3534593
[TBL] [Abstract][Full Text] [Related]
20. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]